Courage Therapeutics is a technology company.
Courage Therapeutics has raised $1.0M across 1 funding round.
Courage Therapeutics has raised $1.0M in total across 1 funding round.
Courage Therapeutics is a pre-clinical stage biopharmaceutical company developing novel therapeutics targeting melanocortin receptors (MC3R and MC4R) to treat eating disorders like anorexia nervosa, binge eating disorder (BED), and obesity.[1][2][3] Founded in 2019 and based in Newton, MA, it serves patients with metabo-psychiatric disorders by modulating brain responses to energy signals, with lead candidates including an MC4R agonist for obesity and an MC3R agonist for anorexia.[1][2] The company has raised $1M in funding, secured a licensing agreement with the University of Michigan, and recently attracted investment from Arsenal Bridge Ventures to advance animal model testing and preclinical programs.[3][5]
Courage Therapeutics emerged in June 2019 as a spinout from Dr. Roger Cone's lab at the University of Michigan, leveraging his pioneering research on melanocortin receptor biology and the molecular basis of feeding behaviors.[1][2] Co-founded by Dr. Roger Cone, a National Academy of Sciences member and Director of the University of Michigan Life Sciences Institute with prior venture success (e.g., Northwest Neurologic acquired by Neurocrine Biosciences), and Daniel Housman, CEO with MIT molecular biology background and exits like Recombinant Data (sold to Deloitte at $15M revenue),[1] the idea stemmed from Cone's IP on novel melanocortin receptor uses.[1][3] Early traction included screening small molecules and peptides that modulate eating via MC3R, MC4R, and STAT3 in animal models, a $1M raise led by Michigan Biomedical Ventures for eating disorder testing, and a University of Michigan licensing deal.[1][3]
Courage rides the wave of neuroendocrine therapies amid surging demand for precision treatments in obesity and eating disorders, fueled by GLP-1 successes like semaglutide and gaps in addressing psychiatric components of weight dysregulation.[2][5] Timing aligns with post-2023 biotech investment rebound in CNS/neurology, where melanocortin pathways offer differentiated mechanisms beyond gut-hormone mimics, targeting central feeding circuits.[1][2] Market forces favor it via University of Michigan ties, mid-continent innovation hubs less saturated than coasts, and VC interest from firms like Arsenal Bridge Ventures syndicating AI-grounded biotech.[5] It influences the ecosystem by advancing academic spinouts, potentially enabling partnerships for rare disorders like ARFID and genetic obesity.[3]
Courage is poised to advance its MC4R/MC3R candidates into IND-enabling studies, with next steps including additional animal efficacy data, partner-seeking for licensing, and expanded funding to fuel preclinical milestones.[2][3][5] Trends like multimodal obesity therapies and metabo-psychiatric integration will shape its path, amplifying impact as eating disorder prevalence rises. Its influence may evolve through acquisitions or big-pharma deals, mirroring Cone's prior successes, solidifying its role in targeted CNS biotech innovation.
Courage Therapeutics has raised $1.0M in total across 1 funding round.
Courage Therapeutics's investors include Adjacent, Aglae Ventures, Brkfst Club, Future Ventures, Galaxy Digital, Johnson & Johnson Innovation, Presight Capital, Thiel Capital, What If Ventures.
Courage Therapeutics has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $1.0M Seed | Adjacent, Aglae Ventures, Brkfst Club, Future Ventures, Galaxy Digital, Johnson & Johnson Innovation, Presight Capital, Thiel Capital, What If Ventures |